RNA sequencing‑based identification of potential targets in acute myeloid leukemia: A case report

El‑Masry,Omar S.; Al‑Amri,Ali M.; Alqatari,Ahlam; Alsamman,Khaldoon

doi:10.3892/br.2020.1349

RNA sequencing‑based identification of potential targets in acute myeloid leukemia: A case report

Authors:
- Omar S. El‑Masry
- Ali M. Al‑Amri
- Ahlam Alqatari
- Khaldoon Alsamman
View Affiliations

Affiliations: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Eastern Province 34212, Kingdom of Saudi Arabia, Department of Internal Medicine/Oncology, College of Medicine, Imam Abdulrahman Bin Faisal University, King Fahd Hospital of The University, Al‑Khobar, Eastern Province 34445, Kingdom of Saudi Arabia, Hematology Laboratory/Hematopathology, College of Medicine, Imam Abdulrahman Bin Faisal University, King Fahd Hospital of The University, Al‑Khobar, Eastern Province 34445, Kingdom of Saudi Arabia
Published online on: August 27, 2020 https://doi.org/10.3892/br.2020.1349
Article Number: 42
Copyright: © El‑Masry et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) refers to heterogenous types of blood cancer which possess a complicated genomic landscape, and multiple novel mutational alterations are frequently being reported. Herein, a case report of a 37‑year old AML patient is presented, who was diagnosed following laboratory investigation after admission. The patient had thrombocytopenia, and three consecutive blast counts of 40, 30 and 41%, respectively. A blood sample was collected for whole‑genome RNA sequencing to understand the transcriptomic profile at the time of diagnosis and compared with a matched female control. Gene expression was quantified using the RSEM software package. Bioinformatics analysis revealed a significant number of differentially expressed genes in the patient, suggesting a marked change in the transcriptomic landscape in this patient. By mining the bioinformatics data and screening the highly expressed genes with ≥80% probability of gene expression, four novel genes were highlighted that may serve as potential future targets in AML patients; Rh associated glycoprotein, succinate receptor 1, transmembrane‑4 L‑six family member‑1 and ADGRA3, although further validation of their value is required.

View Figures

View References

1	Hasserjian RP: Acute myeloid leukemia: Advances in diagnosis and classification. Int J Lab Hematol. 35:358–366. 2013.PubMed/NCBI View Article : Google Scholar
2	Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 33:451–458. 1976.PubMed/NCBI View Article : Google Scholar
3	DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bueso-Ramos C, Jabbour E, Ravandi F, Cortes J and Kantarjian H: Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol. 91:227–232. 2016.PubMed/NCBI View Article : Google Scholar
4	Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–447. 2017.PubMed/NCBI View Article : Google Scholar
5	Lagunas-Rangel FA, Chávez-Valencia V, Gómez-Guijosa MÁ and Cortes-Penagos C: Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res. 11:328–339. 2017.PubMed/NCBI
6	Martelli MP, Sportoletti P, Tiacci E, Martelli MF and Falini B: Mutational landscape of AML with normal cytogenetics: Biological and clinical implications. Blood Rev. 27:13–22. 2013.PubMed/NCBI View Article : Google Scholar
7	Rubnitz JE, Gibson B and Smith FO: Acute myeloid leukemia. Hematol Oncol Clin North Am. 24:35–63. 2010.PubMed/NCBI View Article : Google Scholar
8	Takahashi S: Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol. 4(36)2011.PubMed/NCBI View Article : Google Scholar
9	Batcha AMN, Bamopoulos SA, Kerbs P, Kumar A, Jurinovic V, Rothenberg-Thurley M, Ksienzyk B, Philippou-Massier J, Krebs S, Blum H, et al: Allelic imbalance of recurrently mutated genes in acute myeloid leukaemia. Sci Rep. 9(11796)2019.PubMed/NCBI View Article : Google Scholar
10	Castle JC, Loewer M, Boegel S, Tadmor AD, Boisguerin V, de Graaf J, Paret C, Diken M, Kreiter S, Türeci O and Sahin U: Mutated tumor alleles are expressed according to their DNA frequency. Sci Rep. 4(4743)2014.PubMed/NCBI View Article : Google Scholar
11	Vardiman JW, Harris NL and Brunning RD: The world health organization (WHO) classification of the myeloid neoplasms. Blood. 100:2292–2302. 2002.PubMed/NCBI View Article : Google Scholar
12	Hemsing AL, Hovland R, Tsykunova G and Reikvam H: Trisomy 8 in acute myeloid leukemia. Expert Rev Hematol. 12:947–958. 2019.PubMed/NCBI View Article : Google Scholar
13	Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J and Orazi A: European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 90:1128–1132. 2005.PubMed/NCBI
14	Mortazavi A, Williams BA, McCue K, Schaeffer L and Wold B: Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 5:621–628. 2008.PubMed/NCBI View Article : Google Scholar
15	Wang Z, Gerstein M and Snyder M: RNA-Seq: A revolutionary tool for transcriptomics. Nat Rev Genet. 10:57–63. 2009.PubMed/NCBI View Article : Google Scholar
16	Li B and Dewey CN: RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 12(323)2011.PubMed/NCBI View Article : Google Scholar
17	Tarazona S, Furió-Tarı P, Nueda MJ, Ferrer A and Conesa A: NOISeq: Differential expression in RNA-seq 2013. https://bicoductor.statistik.tu-dortmund.de/packages/3.7/bior/vignettes/NOISwq/inst/doc/NOISeq.pdf.
18	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA: The genome analysis toolkit: A mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303. 2010.PubMed/NCBI View Article : Google Scholar
19	Daver N, Schlenk RF, Russell NH and Levis MJ: Targeting FLT3 mutations in AML: Review of current knowledge and evidence. Leukemia. 33:299–312. 2019.PubMed/NCBI View Article : Google Scholar
20	Berman JN, Gerbing RB, Alonzo TA, Ho PA, Miller K, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, et al: Prevalence and clinical implications of NRAS mutations in childhood AML: A report from the Children's oncology group. Leukemia. 25:1039–1042. 2011.PubMed/NCBI View Article : Google Scholar
21	Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI and Schimmer AD: Biological and clinical consequences of NPM1 mutations in AML. Leukemia. 31:798–807. 2017.PubMed/NCBI View Article : Google Scholar
22	Spiess K, Bagger SO, Torz LJ, Jensen KHR, Walser AL, Kvam JM, Møgelmose ASK, Daugvilaite V, Junnila RK, Hjortø GM and Rosenkilde MM: Arrestin-independent constitutive endocytosis of GPR125/ADGRA3. Ann N Y Acad Sci. 1456:186–199. 2019.PubMed/NCBI View Article : Google Scholar
23	Maiga A, Lemieux S, Pabst C, Lavallée VP, Bouvier M, Sauvageau G and Hébert J: Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: Identification of potential disease-specific targets. Blood Cancer J. 6(e431)2016.PubMed/NCBI View Article : Google Scholar
24	Wu Y, Chen W, Gong L, Ke C, Wang H and Cai Y: Elevated G-protein receptor 125 (GPR125) expression predicts good outcomes in colorectal cancer and inhibits wnt/β-catenin signaling pathway. Med Sci Monitor. 24:6608–6616. 2018.PubMed/NCBI View Article : Google Scholar
25	Institute NC: Genomic data commons data portal. https://portal.gdc.cancer.gov/genes/ENSG00000152990. J 2020.
26	Institute NC: Genomic data commons data portal. https://portal.gdc.cancer.gov/genes/ENSG00000198829. J 2020.
27	Louer EMM, Lores-Motta L, Ion AM, Den Hollander AI and Deen PMT: Single nucleotide polymorphism rs13079080 is associated with differential regulation of the succinate receptor 1 (SUCNR1) gene by miRNA-4470. RNA Biol. 16:1547–1554. 2019.PubMed/NCBI View Article : Google Scholar
28	Mu X, Zhao T, Xu C, Shi W, Geng B, Shen J, Zhang C, Pan J, Yang J, Hu S, et al: Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation. Oncotarget. 8:13174–13185. 2017.PubMed/NCBI View Article : Google Scholar
29	Thutkawkorapin J, Picelli S, Kontham V, Liu T, Nilsson D and Lindblom A: Exome sequencing in one family with gastric- and rectal cancer. BMC Genet. 17(41)2016.PubMed/NCBI View Article : Google Scholar
30	Macaulay IC, Tijssen MR, Thijssen-Timmer DC, Gusnanto A, Steward M, Burns P, Langford CF, Ellis PD, Dudbridge F, Zwaginga JJ, et al: Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood. 109:3260–3269. 2007.PubMed/NCBI View Article : Google Scholar
31	Ariza AC, Deen PMT and Robben JH: The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions. Front Endocrinol (Lausanne). 3(22)2012.PubMed/NCBI View Article : Google Scholar
32	Hakak Y, Lehmann-Bruinsma K, Phillips S, Le T, Liaw C, Connolly DT and Behan DP: The role of the GPR91 ligand succinate in hematopoiesis. J Leukoc Biol. 85:837–843. 2009.PubMed/NCBI View Article : Google Scholar
33	Chen H, Pan T, Liu P, Wang P and Xu S: Baihu Jia Guizhi decoction improves rheumatoid arthritis inflammation by regulating succinate/SUCNR1 metabolic signaling pathway. Evid Based Complement Alternat Med. 2019(3258572)2019.PubMed/NCBI View Article : Google Scholar
34	Bardella C, Pollard PJ and Tomlinson I: SDH mutations in cancer. Biochim Biophys Acta. 1807:1432–1443. 2011.PubMed/NCBI View Article : Google Scholar
35	Ricketts C, Woodward ER, Killick P, Morris MR, Astuti D, Latif F and Maher ER: Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 100:1260–1262. 2008.PubMed/NCBI View Article : Google Scholar
36	Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, et al: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 287:848–851. 2000.PubMed/NCBI View Article : Google Scholar
37	Zhao T, Mu X and You Q: Succinate: An initiator in tumorigenesis and progression. Oncotarget. 8:53819–53828. 2017.PubMed/NCBI View Article : Google Scholar
38	Chen BS, Xu ZX, Xu X, Cai Y, Han YL, Wang J, Xia SH, Hu H, Wei F, Wu M and Wang MR: RhCG is downregulated in oesophageal squamous cell carcinomas, but expressed in multiple squamous epithelia. Eur J Cancer. 38:1927–1936. 2002.PubMed/NCBI View Article : Google Scholar
39	Ye L, Pu C, Tang J, Wang Y, Wang C, Qiu Z, Xiang T, Zhang Y and Peng W: Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis. Respir Res. 20(106)2019.PubMed/NCBI View Article : Google Scholar
40	Yang JC, Zhang Y, He SJ, Li MM, Cai XL, Wang H, Xu LM and Cao J: TM4SF1 promotes metastasis of pancreatic cancer via regulating the expression of DDR1. Sci Rep. 7(45895)2017.PubMed/NCBI View Article : Google Scholar